Rationale Sepsis is a life-threatening condition arising from a dysregulated immune response to infection, leading to tissue damage, organ failure, and potentially death. Delayed diagnosis significantly increases morbidity and mortality. The Global Burden of Disease study (2017) estimated 49 million annual sepsis cases worldwide, accounting for 11 million deaths. In response, the WHO recognized sepsis as a global health priority, emphasizing early detection and timely treatment. Although clinical scoring systems, such as APACHE II, SIRS, SOFA, and EWS (including NEWS2 and qSOFA), assist in recognizing sepsis, each has its limitations. These systems often lack specificity, are susceptible to human error, and depend on discrete, manually captured measurements. Furthermore, their design does not support real-time or predictive monitoring, particularly in ambulatory or general ward settings, which limits their applicability for early intervention. Wearable continuous monitoring offers a promising solution by enabling dynamic trend analysis across multiple physiological parameters. The Corsano CardioWatch 287-2 provides continuous measurement of heart rate, respiratory rate, oxygen saturation, temperature, and cuff-based blood pressure equivalents, offering an integrated foundation for automated early warning algorithms. Study Objectives This study evaluates the performance and feasibility of continuous vital sign monitoring via the Corsano CardioWatch 287-2 to detect early signs of sepsis. Specifically, it aims to: • Validate the Cor-NEWS2, Cor-EWS, and Cor-EWS-AI early warning algorithms. • Compare sensitivity, specificity, and time-to-onset performance with conventional tools • Assess the integration feasibility of Corsano algorithms in clinical decision-making. • Evaluate user experience and system integration in clinical workflows. • Evaluate patient adherence and acceptance of wearable technology. Study Design This is a prospective, single-center observational cohort study at Universitätsmedizin Greifswald. Patients admitted to the general ward or medium care following thoracic or gastrointestinal surgery and identified as at high risk for clinical deterioration are eligible. Participants wear the CardioWatch 287-2 throughout their hospital stay, while clinicians remain blinded to real-time data, preserving standard-of-care treatment pathways. Inclusion Criteria • Adults aged ≥18 years • Undergoing thoracic or gastrointestinal surgery • Admitted to the general ward or medium care • Able to provide informed consent Exclusion Criteria • Inability to provide informed consent • Inability to wear the CardioWatch 287-2 (e.g., due to skin injury, amputation, allergic reaction) • Inability to receive cuff-based blood pressure measurement • Significant cognitive impairment, pregnancy, or palliative status Current Status As of the latest update, 34 patients have been enrolled in the ICU setting. However, none have met the criteria for sepsis onset to date. Recruitment is actively ongoing. While sepsis cases have not yet been captured in this early stage, clinical staff report exceptionally positive feedback on usability and integration for the Corsano CardioWatch 287-2. Usability Insights & Future Implementation Due to the high acceptance and ease of use reported by healthcare professionals, hospital-wide implementation of Corsano’s continuous monitoring system is currently under consideration at Universitätsmedizin Greifswald. This direction is supported by emerging scientific literature, including a recent publication: The role of the Corsano CardioWatch in continuous vital sign monitoring for early sepsis detection – Critical Care (2025), Biomed Central [https://doi.org/10.1186/s13054-025-05365-z] Timeline Status: Recruiting Patients Start: April 2024 Estimated duration: 18 months Study center Universitätsmedizin Greifswald, Germany